Myelodysplastic Syndromes Treatment (PDQ®): Patient Version
This PDQ cancer information summary has current information about the treatment of myelodysplastic syndromes myelodysplastic syndromes:
Myelodysplastic Syndromes (MDS)
Getting personal with myelodysplastic syndromes: is now the right time?
Commonly used scoring systems rely on blood counts, histological and cytological examination of bone marrow bone marrow: The soft, spongy tissue inside most bones.
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Immunosuppressive therapy Immunosuppressive therapy: Immunosuppressive drug therapy lowers your body's immune response.
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
Myeloid neoplasms, including myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A grou
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge
A patient with a diagnosis of myelodysplastic syndrome (MDS) with isolated 5q deletion underwent repeat bone marrow biopsy bone marrow biopsy: A medical procedur
Clonal Hematopoiesis and therapy related MDS/AML
Clonal Hematopoiesis Hematopoiesis: (hi-mat-uh-poy-EE-suss) The process of making blood cells in the bone marrow. is defined as the presence of mutations in peripheral blo
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We evaluated the efficacy and safety of the smoothened inhibitor glasdegib in HMA-failure MDS (n = 35, median age 73 years).